SC
TRIB

Skylands Capital’s Trinity Biotech TRIB Stock Holding History

Skylands Capital’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,080
Closed -$2.14M – 196
2016
Q3 		$2.14M Buy
1,080
+6
+0.6% +$11.2K 0.34% 76
2016
Q2 		$1.83M Sell
1,074
-555
-34% -$938K 0.3% 75
2016
Q1 		$2.85M Buy
1,629
+92
+6% +$146K 0.46% 56
2015
Q4 		$2.71M Buy
1,537
+499
+48% +$884K 0.39% 65
2015
Q3 		$1.78M Sell
1,038
-418
-29% -$1.01M 0.24% 89
2015
Q2 		$3.94M Sell
1,456
-24
-2% -$62.3K 0.42% 53
2015
Q1 		$4.27M Buy
1,480
+185
+14% +$513K 0.43% 49
2014
Q4 		$3.4M Buy
1,295
+234
+22% +$605K 0.35% 60
2014
Q3 		$2.91M Buy
1,061
+824
+348% +$2.68M 0.3% 70
2014
Q2 		$818K Buy
237
+116
+96% +$412K 0.08% 167
2014
Q1 		$441K Hold
121
– – 0.05% 186
2013
Q4 		$458K Sell
121
-42
-26% -$151K 0.05% 173
2013
Q3 		$531K Buy
+163
New +$477K 0.06% 181

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Skylands Capital's TRIB Position: Q4 2016 in Review

Skylands Capital sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 1,080 shares — an estimated $2.14M sold.

Skylands Capital first reported a position in TRIB in Q3 2013 and held it in 13 quarters. The position peaked at $4.27M in Q1 2015. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Skylands Capital reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Skylands Capital sold 1,080 Trinity Biotech shares in Q4 2016, an estimated $2.14M.
  • Skylands Capital first reported a position in Trinity Biotech in Q3 2013 and held it in 13 quarters.
  • Skylands Capital's Trinity Biotech position peaked at $4.27M in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Skylands Capital's 13F filing for Q4 2016, filed 19 Jan 2017.